ES2339450T3 - Derivados de estrogenos como inhibidores de esteroide sulfatasa. - Google Patents

Info

Publication number

ES2339450T3

ES2339450T3 ES04713124T ES04713124T ES2339450T3 ES 2339450 T3 ES2339450 T3 ES 2339450T3 ES 04713124 T ES04713124 T ES 04713124T ES 04713124 T ES04713124 T ES 04713124T ES 2339450 T3 ES2339450 T3 ES 2339450T3

Authority

ES

Spain

Prior art keywords

group

compound according

alkyl

baselineskip

compound

Prior art date

2003-03-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Lifetime

Links

• Espacenet
• Global Dossier
• Discuss

• 102100038021 Steryl-sulfatase Human genes 0.000 title claims description 47
• 108010087999 Steryl-Sulfatase Proteins 0.000 title claims description 29
• 239000003112 inhibitor Substances 0.000 title description 26
• 150000001875 compounds Chemical class 0.000 claims abstract description 252
• 125000000217 alkyl group Chemical group 0.000 claims abstract description 196
• 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 62
• 125000003118 aryl group Chemical group 0.000 claims abstract description 39
• 125000005842 heteroatom Chemical group 0.000 claims abstract description 39
• 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 30
• 125000003342 alkenyl group Chemical group 0.000 claims abstract description 27
• 125000004122 cyclic group Chemical group 0.000 claims abstract description 26
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract description 17
• 125000002252 acyl group Chemical group 0.000 claims abstract description 16
• 230000003637 steroidlike Effects 0.000 claims abstract description 15
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims abstract description 11
• 125000000565 sulfonamide group Chemical group 0.000 claims abstract description 7
• 125000002560 nitrile group Chemical group 0.000 claims abstract description 6
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims abstract description 4
• 125000005647 linker group Chemical group 0.000 claims abstract description 3
• 239000000203 mixture Substances 0.000 claims description 102
• 230000000694 effects Effects 0.000 claims description 92
• -1 methoxy, ethoxy Chemical group 0.000 claims description 82
• 206010028980 Neoplasm Diseases 0.000 claims description 67
• 239000003814 drug Substances 0.000 claims description 56
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 42
• 230000015572 biosynthetic process Effects 0.000 claims description 39
• 102000029749 Microtubule Human genes 0.000 claims description 38
• 108091022875 Microtubule Proteins 0.000 claims description 38
• 210000004688 microtubule Anatomy 0.000 claims description 38
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 38
• 230000006907 apoptotic process Effects 0.000 claims description 36
• 125000001424 substituent group Chemical group 0.000 claims description 35
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
• 201000010099 disease Diseases 0.000 claims description 30
• 239000004215 Carbon black (E152) Substances 0.000 claims description 29
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 29
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 29
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
• 230000022131 cell cycle Effects 0.000 claims description 28
• 229930195733 hydrocarbon Natural products 0.000 claims description 28
• 238000004519 manufacturing process Methods 0.000 claims description 28
• 102000003390 tumor necrosis factor Human genes 0.000 claims description 28
• 150000002430 hydrocarbons Chemical class 0.000 claims description 25
• 229910052799 carbon Inorganic materials 0.000 claims description 23
• 238000002560 therapeutic procedure Methods 0.000 claims description 23
• 230000004190 glucose uptake Effects 0.000 claims description 21
• 239000003607 modifier Substances 0.000 claims description 19
• 102000004127 Cytokines Human genes 0.000 claims description 18
• 108090000695 Cytokines Proteins 0.000 claims description 18
• 230000010261 cell growth Effects 0.000 claims description 18
• 125000003545 alkoxy group Chemical group 0.000 claims description 17
• 230000005747 tumor angiogenesis Effects 0.000 claims description 16
• 230000002401 inhibitory effect Effects 0.000 claims description 13
• 125000002947 alkylene group Chemical group 0.000 claims description 12
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
• 230000004614 tumor growth Effects 0.000 claims description 12
• 125000005843 halogen group Chemical group 0.000 claims description 11
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
• 239000008194 pharmaceutical composition Substances 0.000 claims description 11
• 229940088597 hormone Drugs 0.000 claims description 10
• 239000005556 hormone Substances 0.000 claims description 10
• 230000008512 biological response Effects 0.000 claims description 9
• 229910052739 hydrogen Inorganic materials 0.000 claims description 9
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 9
• 229910052717 sulfur Inorganic materials 0.000 claims description 9
• 230000001225 therapeutic effect Effects 0.000 claims description 9
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
• 230000002411 adverse Effects 0.000 claims description 6
• 230000001413 cellular effect Effects 0.000 claims description 6
• 239000011593 sulfur Substances 0.000 claims description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
• 229940124530 sulfonamide Drugs 0.000 claims description 5
• 150000003456 sulfonamides Chemical class 0.000 claims description 5
• 230000003399 chemotactic effect Effects 0.000 claims description 4
• 230000011132 hemopoiesis Effects 0.000 claims description 4
• 230000002537 thrombolytic effect Effects 0.000 claims description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
• 102000016359 Fibronectins Human genes 0.000 claims description 3
• 108010067306 Fibronectins Proteins 0.000 claims description 3
• 125000000304 alkynyl group Chemical group 0.000 claims description 3
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
• 229910052736 halogen Inorganic materials 0.000 claims description 3
• 150000002367 halogens Chemical class 0.000 claims description 3
• 230000002949 hemolytic effect Effects 0.000 claims description 3
• 239000003446 ligand Substances 0.000 claims description 3
• 102000006240 membrane receptors Human genes 0.000 claims description 3
• 239000008024 pharmaceutical diluent Substances 0.000 claims description 3
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 3
• 230000003449 preventive effect Effects 0.000 claims description 3
• 102000037983 regulatory factors Human genes 0.000 claims description 3
• 108091008025 regulatory factors Proteins 0.000 claims description 3
• 229960005486 vaccine Drugs 0.000 claims description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
• 125000003277 amino group Chemical group 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 210000002744 extracellular matrix Anatomy 0.000 claims description 2
• 229910052731 fluorine Inorganic materials 0.000 claims description 2
• 239000011737 fluorine Substances 0.000 claims description 2
• 125000004051 hexyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
• 210000000265 leukocyte Anatomy 0.000 claims description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
• 230000004936 stimulating effect Effects 0.000 claims description 2
• PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical group C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 2
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
• 239000003146 anticoagulant agent Substances 0.000 claims 1
• 239000003102 growth factor Substances 0.000 claims 1
• 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 348
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 243
• 210000004027 cell Anatomy 0.000 description 125
• 239000000243 solution Substances 0.000 description 100
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 96
• 238000006243 chemical reaction Methods 0.000 description 75
• 238000000034 method Methods 0.000 description 71
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 62
• 102000005262 Sulfatase Human genes 0.000 description 61
• 108060007951 sulfatase Proteins 0.000 description 61
• 239000012267 brine Substances 0.000 description 58
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 58
• 239000007787 solid Substances 0.000 description 56
• 229960003399 estrone Drugs 0.000 description 55
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 54
• 238000011282 treatment Methods 0.000 description 52
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 50
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 47
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 44
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 41
• 239000012074 organic phase Substances 0.000 description 40
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
• 238000004440 column chromatography Methods 0.000 description 38
• 239000002904 solvent Substances 0.000 description 37
• 239000000047 product Substances 0.000 description 36
• 239000000262 estrogen Substances 0.000 description 34
• 230000014509 gene expression Effects 0.000 description 34
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
• 229940011871 estrogen Drugs 0.000 description 33
• 239000000843 powder Substances 0.000 description 32
• 150000002148 esters Chemical class 0.000 description 31
• 108090000623 proteins and genes Proteins 0.000 description 29
• 150000003431 steroids Chemical class 0.000 description 29
• 208000026310 Breast neoplasm Diseases 0.000 description 27
• 239000012230 colorless oil Substances 0.000 description 27
• 229910052757 nitrogen Inorganic materials 0.000 description 27
• 229960005309 estradiol Drugs 0.000 description 26
• 238000003818 flash chromatography Methods 0.000 description 26
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 25
• 235000019341 magnesium sulphate Nutrition 0.000 description 25
• 150000002894 organic compounds Chemical class 0.000 description 25
• 229910052681 coesite Inorganic materials 0.000 description 24
• 229910052906 cristobalite Inorganic materials 0.000 description 24
• 239000000377 silicon dioxide Substances 0.000 description 24
• 235000012239 silicon dioxide Nutrition 0.000 description 24
• 229910052682 stishovite Inorganic materials 0.000 description 24
• 229910052905 tridymite Inorganic materials 0.000 description 24
• 229940079593 drug Drugs 0.000 description 23
• 230000005764 inhibitory process Effects 0.000 description 23
• 239000003921 oil Substances 0.000 description 23
• 206010006187 Breast cancer Diseases 0.000 description 22
• 238000003756 stirring Methods 0.000 description 22
• 102000004169 proteins and genes Human genes 0.000 description 21
• AQSNIXKAKUZPSI-SSTWWWIQSA-N (9β,13α,14β,17α)-2-methoxyestra-1,3,5(10)-triene-3,17-diyl disulfamate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](OS(N)(=O)=O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(OS(N)(=O)=O)=C1 AQSNIXKAKUZPSI-SSTWWWIQSA-N 0.000 description 20
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
• 238000004587 chromatography analysis Methods 0.000 description 20
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 19
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
• 208000035475 disorder Diseases 0.000 description 18
• 108010005041 estrone sulfatase Proteins 0.000 description 18
• 230000012010 growth Effects 0.000 description 18
• 235000018102 proteins Nutrition 0.000 description 18
• 150000001413 amino acids Chemical class 0.000 description 17
• 229910000104 sodium hydride Inorganic materials 0.000 description 17
• 210000001519 tissue Anatomy 0.000 description 17
• 239000002253 acid Chemical class 0.000 description 16
• 230000002757 inflammatory effect Effects 0.000 description 16
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
• 229930182833 estradiol Natural products 0.000 description 15
• 238000001727 in vivo Methods 0.000 description 15
• 230000004044 response Effects 0.000 description 15
• JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 14
• 206010061218 Inflammation Diseases 0.000 description 14
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 14
• JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 14
• 230000004054 inflammatory process Effects 0.000 description 14
• 239000012071 phase Substances 0.000 description 14
• QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 14
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
• 125000000623 heterocyclic group Chemical group 0.000 description 13
• 239000012312 sodium hydride Substances 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 238000003786 synthesis reaction Methods 0.000 description 13
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 13
• 210000005239 tubule Anatomy 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
• 229930012538 Paclitaxel Natural products 0.000 description 12
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
• 230000001076 estrogenic effect Effects 0.000 description 12
• 230000011278 mitosis Effects 0.000 description 12
• 229960001592 paclitaxel Drugs 0.000 description 12
• 229960002847 prasterone Drugs 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 239000003981 vehicle Substances 0.000 description 12
• 102000004243 Tubulin Human genes 0.000 description 11
• 108090000704 Tubulin Proteins 0.000 description 11
• 125000004429 atom Chemical group 0.000 description 11
• 230000008901 benefit Effects 0.000 description 11
• 210000000349 chromosome Anatomy 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 125000003729 nucleotide group Chemical group 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 11
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
• 108020004414 DNA Proteins 0.000 description 10
• 241000196324 Embryophyta Species 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
• 229940024606 amino acid Drugs 0.000 description 10
• 235000001014 amino acid Nutrition 0.000 description 10
• 230000001419 dependent effect Effects 0.000 description 10
• 239000011159 matrix material Substances 0.000 description 10
• 210000004940 nucleus Anatomy 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 10
• QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 10
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 9
• 241000235070 Saccharomyces Species 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 230000033115 angiogenesis Effects 0.000 description 9
• 210000000481 breast Anatomy 0.000 description 9
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
• 150000001336 alkenes Chemical class 0.000 description 8
• 229960001348 estriol Drugs 0.000 description 8
• 239000001257 hydrogen Substances 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 230000003389 potentiating effect Effects 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 239000013598 vector Substances 0.000 description 8
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 7
• 102000014654 Aromatase Human genes 0.000 description 7
• 108010078554 Aromatase Proteins 0.000 description 7
• 230000006820 DNA synthesis Effects 0.000 description 7
• 239000007832 Na2SO4 Substances 0.000 description 7
• 206010033128 Ovarian cancer Diseases 0.000 description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 description 7
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
• 239000010779 crude oil Substances 0.000 description 7
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
• KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 7
• 210000003527 eukaryotic cell Anatomy 0.000 description 7
• 210000002950 fibroblast Anatomy 0.000 description 7
• 108020001507 fusion proteins Proteins 0.000 description 7
• 102000037865 fusion proteins Human genes 0.000 description 7
• 239000002953 phosphate buffered saline Substances 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 238000010992 reflux Methods 0.000 description 7
• 229910052938 sodium sulfate Inorganic materials 0.000 description 7
• 235000011152 sodium sulphate Nutrition 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 230000009466 transformation Effects 0.000 description 7
• IBAFAEHLNXQMQA-OFLQVFCSSA-N (8r,9s,10s,13s,14s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C1C(O)CC[C@]2(C)[C@H]3CC[C@](C)(C(=CC4)O)[C@@H]4[C@@H]3CCC21 IBAFAEHLNXQMQA-OFLQVFCSSA-N 0.000 description 6
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 6
• CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 6
• QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 6
• 108091060290 Chromatid Proteins 0.000 description 6
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 230000009471 action Effects 0.000 description 6
• 235000019270 ammonium chloride Nutrition 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 210000004718 centriole Anatomy 0.000 description 6
• 210000004756 chromatid Anatomy 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 6
• 230000001575 pathological effect Effects 0.000 description 6
• 238000001953 recrystallisation Methods 0.000 description 6
• 235000017557 sodium bicarbonate Nutrition 0.000 description 6
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 5
• 102000003846 Carbonic anhydrases Human genes 0.000 description 5
• 108090000209 Carbonic anhydrases Proteins 0.000 description 5
• 102000015696 Interleukins Human genes 0.000 description 5
• 108010063738 Interleukins Proteins 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 5
• 239000003886 aromatase inhibitor Substances 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 230000032823 cell division Effects 0.000 description 5
• 238000004090 dissolution Methods 0.000 description 5
• 230000002500 effect on skin Effects 0.000 description 5
• 102000015694 estrogen receptors Human genes 0.000 description 5
• 108010038795 estrogen receptors Proteins 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 229940047122 interleukins Drugs 0.000 description 5
• 230000003211 malignant effect Effects 0.000 description 5
• 150000002825 nitriles Chemical class 0.000 description 5
• 229910052763 palladium Inorganic materials 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 239000011541 reaction mixture Substances 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
• YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 4
• KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 description 4
• 108010076504 Protein Sorting Signals Proteins 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 229940123142 Steroid sulfatase inhibitor Drugs 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 4
• 230000001772 anti-angiogenic effect Effects 0.000 description 4
• 229940046844 aromatase inhibitors Drugs 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
• 230000021953 cytokinesis Effects 0.000 description 4
• 150000002009 diols Chemical class 0.000 description 4
• 239000002158 endotoxin Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• 235000019256 formaldehyde Nutrition 0.000 description 4
• 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 4
• 230000002538 fungal effect Effects 0.000 description 4
• 230000003054 hormonal effect Effects 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 238000011065 in-situ storage Methods 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
• 238000004452 microanalysis Methods 0.000 description 4
• 210000001589 microsome Anatomy 0.000 description 4
• 230000004770 neurodegeneration Effects 0.000 description 4
• 238000011580 nude mouse model Methods 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 210000002826 placenta Anatomy 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 239000004576 sand Substances 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 238000010998 test method Methods 0.000 description 4
• 125000003944 tolyl group Chemical group 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• AQWFDYRHOGVKFU-MQJTVSLUSA-N (8r,9s,13s,14s)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CCC1=C2C=C(CC)C(O)=C1 AQWFDYRHOGVKFU-MQJTVSLUSA-N 0.000 description 3
• MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 3
• 241000193830 Bacillus <bacterium> Species 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 239000003098 androgen Substances 0.000 description 3
• 229960005471 androstenedione Drugs 0.000 description 3
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 230000009087 cell motility Effects 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 150000002167 estrones Chemical class 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 239000013067 intermediate product Substances 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 3
• 208000015122 neurodegenerative disease Diseases 0.000 description 3
• 201000001119 neuropathy Diseases 0.000 description 3
• 230000007823 neuropathy Effects 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 238000006116 polymerization reaction Methods 0.000 description 3
• 239000011698 potassium fluoride Substances 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000004611 spectroscopical analysis Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 230000001629 suppression Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 206010043778 thyroiditis Diseases 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• 239000002699 waste material Substances 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 2
• WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 2
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
• 241000228212 Aspergillus Species 0.000 description 2
• 241000228245 Aspergillus niger Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 230000010190 G1 phase Effects 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000014429 Insulin-like growth factor Human genes 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108050009288 Interleukin-19 Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 108010002335 Interleukin-9 Proteins 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 108010014691 Lithostathine Proteins 0.000 description 2
• 102100027361 Lithostathine-1-alpha Human genes 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 241000589516 Pseudomonas Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 102000003800 Selectins Human genes 0.000 description 2
• 108090000184 Selectins Proteins 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 241000187747 Streptomyces Species 0.000 description 2
• 230000024932 T cell mediated immunity Effects 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 241000223259 Trichoderma Species 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• NDDAQHROMJDMKS-XFYXLWKMSA-N [(2s,3s,5s,8r,9s,10s,13s,14s)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride Chemical compound Cl.C1[C@H](N)[C@@H](O)C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 NDDAQHROMJDMKS-XFYXLWKMSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
• 230000001833 anti-estrogenic effect Effects 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 208000036815 beta tubulin Diseases 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000003783 cell cycle assay Methods 0.000 description 2
• 239000013553 cell monolayer Substances 0.000 description 2
• 210000002230 centromere Anatomy 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000003501 co-culture Methods 0.000 description 2
• 229960001338 colchicine Drugs 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
• 229960000452 diethylstilbestrol Drugs 0.000 description 2
• POCFBDFTJMJWLG-UHFFFAOYSA-N dihydrosinapic acid methyl ester Natural products COC(=O)CCC1=CC(OC)=C(O)C(OC)=C1 POCFBDFTJMJWLG-UHFFFAOYSA-N 0.000 description 2
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 230000002357 endometrial effect Effects 0.000 description 2
• 210000004696 endometrium Anatomy 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 150000002159 estradiols Chemical class 0.000 description 2
• PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
• 239000000328 estrogen antagonist Substances 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 230000035558 fertility Effects 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 239000003862 glucocorticoid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000004554 glutamine Nutrition 0.000 description 2
• 229960002743 glutamine Drugs 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 238000005805 hydroxylation reaction Methods 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 230000007813 immunodeficiency Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 230000000937 inactivator Effects 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000008880 microtubule cytoskeleton organization Effects 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 229940097496 nasal spray Drugs 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 210000000633 nuclear envelope Anatomy 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000003169 placental effect Effects 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
• 229950009829 prasterone sulfate Drugs 0.000 description 2
• DIJBBUIOWGGQOP-QGVNFLHTSA-N pregnenolone sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DIJBBUIOWGGQOP-QGVNFLHTSA-N 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 230000031877 prophase Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 235000004252 protein component Nutrition 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 239000012047 saturated solution Substances 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 229960001153 serine Drugs 0.000 description 2
• 235000004400 serine Nutrition 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000000021 stimulant Substances 0.000 description 2
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000016853 telophase Effects 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 229960002898 threonine Drugs 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• 229960000103 thrombolytic agent Drugs 0.000 description 2
• 229960004441 tyrosine Drugs 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 235000002374 tyrosine Nutrition 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• VRYALKFFQXWPIH-PPNYQRBUSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=C[C@H]([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-PPNYQRBUSA-N 0.000 description 1
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
• PEXPJFWTSZLEAQ-YSYMNNNUSA-N (8r,9s,13s,14s,16r,17r)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)[C@H](O)C[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 PEXPJFWTSZLEAQ-YSYMNNNUSA-N 0.000 description 1
• CQOQDQWUFQDJMK-UPCNGNSLSA-N (8r,9s,13s,14s,17r)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound C([C@@H]12)C[C@]3(C)[C@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-UPCNGNSLSA-N 0.000 description 1
• HLCRYAZDZCJZFG-BDXSIMOUSA-N (8s,9s,13s,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CC=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HLCRYAZDZCJZFG-BDXSIMOUSA-N 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• 229930182834 17alpha-Estradiol Natural products 0.000 description 1
• VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
• WHEUWNKSCXYKBU-UHFFFAOYSA-N 2-Methoxyestron Natural products C12CCC3(C)C(=O)CCC3C2CCC2=C1C=C(OC)C(O)=C2 WHEUWNKSCXYKBU-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
• WHEUWNKSCXYKBU-QPWUGHHJSA-N 2-methoxyestrone Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 WHEUWNKSCXYKBU-QPWUGHHJSA-N 0.000 description 1
• NJBCRXCAPCODGX-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)propan-1-amine Chemical compound CC(C)CNCC(C)C NJBCRXCAPCODGX-UHFFFAOYSA-N 0.000 description 1
• ZLXFMMQQGQQKFC-UHFFFAOYSA-N 2-phenanthren-3-ylacetic acid Chemical compound C1=CC=C2C3=CC(CC(=O)O)=CC=C3C=CC2=C1 ZLXFMMQQGQQKFC-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 108700036240 26S proteasome regulatory subunit 8 Proteins 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 206010065040 AIDS dementia complex Diseases 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 229940122815 Aromatase inhibitor Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241001513093 Aspergillus awamori Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 240000006439 Aspergillus oryzae Species 0.000 description 1
• 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• DBNXUWPTANVESP-NDPCYUFKSA-N C(C)C=1C(=CC2=C([C@H]3CC[C@@]4(C(CC[C@H]4[C@@H]3CC2)OS(=O)(=O)C)C)C=1)OS(N)(=O)=O Chemical compound C(C)C=1C(=CC2=C([C@H]3CC[C@@]4(C(CC[C@H]4[C@@H]3CC2)OS(=O)(=O)C)C)C=1)OS(N)(=O)=O DBNXUWPTANVESP-NDPCYUFKSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000014912 Central Nervous System Infections Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
• 208000002691 Choroiditis Diseases 0.000 description 1
• 101150065749 Churc1 gene Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 208000027932 Collagen disease Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 201000006306 Cor pulmonale Diseases 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
• 241000257465 Echinoidea Species 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 206010053177 Epidermolysis Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 229920013685 Estron Polymers 0.000 description 1
• 102100029782 Eukaryotic translation initiation factor 3 subunit I Human genes 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 101710112457 Exoglucanase Proteins 0.000 description 1
• 208000001382 Experimental Melanoma Diseases 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• 230000037059 G2/M phase arrest Effects 0.000 description 1
• 101150094690 GAL1 gene Proteins 0.000 description 1
• 102100028501 Galanin peptides Human genes 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
• 108091052347 Glucose transporter family Proteins 0.000 description 1
• 102000042092 Glucose transporter family Human genes 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 101150069554 HIS4 gene Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 208000008899 Habitual abortion Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 206010022557 Intermediate uveitis Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
• 102000010638 Kinesin Human genes 0.000 description 1
• 108010063296 Kinesin Proteins 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 229910010082 LiAlH Inorganic materials 0.000 description 1
• 229910010084 LiAlH4 Inorganic materials 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229940124148 Macrophage inhibitor Drugs 0.000 description 1
• 208000001344 Macular Edema Diseases 0.000 description 1
• 206010025415 Macular oedema Diseases 0.000 description 1
• 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
• 206010025538 Malignant ascites Diseases 0.000 description 1
• 206010026865 Mass Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 229910017917 NH4 Cl Inorganic materials 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 1
• 206010067572 Oestrogenic effect Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000005141 Otitis Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 206010035138 Placental insufficiency Diseases 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 208000003971 Posterior uveitis Diseases 0.000 description 1
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
• 206010036631 Presenile dementia Diseases 0.000 description 1
• 102100038239 Protein Churchill Human genes 0.000 description 1
• 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
• 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 108091006296 SLC2A1 Proteins 0.000 description 1
• 229910006124 SOCl2 Inorganic materials 0.000 description 1
• 101150014136 SUC2 gene Proteins 0.000 description 1
• 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000014151 Stomatognathic disease Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 229940123155 T cell inhibitor Drugs 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000001001 X-linked ichthyosis Diseases 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 229960003767 alanine Drugs 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001347 alkyl bromides Chemical class 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
• 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
• 230000006986 amnesia Effects 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000031016 anaphase Effects 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 229940044684 anti-microtubule agent Drugs 0.000 description 1
• 230000001621 anti-mitogenic effect Effects 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 229940076006 cell cycle modulator Drugs 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 230000001659 chemokinetic effect Effects 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 210000001726 chromosome structure Anatomy 0.000 description 1
• 210000004081 cilia Anatomy 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 235000001671 coumarin Nutrition 0.000 description 1
• 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013058 crude material Substances 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 210000000695 crystalline len Anatomy 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001236 detergent effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 102000013035 dynein heavy chain Human genes 0.000 description 1
• 108060002430 dynein heavy chain Proteins 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 101150004703 eIF3i gene Proteins 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• 208000002296 eclampsia Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000009483 enzymatic pathway Effects 0.000 description 1
• 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 150000002166 estriols Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001033 ether group Chemical group 0.000 description 1
• MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
• BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• SLAFUPJSGFVWPP-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 SLAFUPJSGFVWPP-UHFFFAOYSA-M 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 108010052621 fas Receptor Proteins 0.000 description 1
• 102000018823 fas Receptor Human genes 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 210000003495 flagella Anatomy 0.000 description 1
• 229930003944 flavone Natural products 0.000 description 1
• 150000002213 flavones Chemical class 0.000 description 1
• 235000011949 flavones Nutrition 0.000 description 1
• 229940028334 follicle stimulating hormone Drugs 0.000 description 1
• 210000003918 fraction a Anatomy 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
• 229960001867 guaiacol Drugs 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002439 hemostatic effect Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 150000004678 hydrides Chemical class 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• FLQUDUCNBDGCRI-UHFFFAOYSA-N hydroxy-sulfanyl-sulfidophosphanium Chemical compound SP(S)=O FLQUDUCNBDGCRI-UHFFFAOYSA-N 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000014726 immortalization of host cell Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 229950000038 interferon alfa Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 210000003963 intermediate filament Anatomy 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960003136 leucine Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000010230 macular retinal edema Diseases 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000021121 meiosis Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000006993 memory improvement Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
• LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
• JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 210000003632 microfilament Anatomy 0.000 description 1
• 231100000782 microtubule inhibitor Toxicity 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• BAPROVDXKNPHAM-UHFFFAOYSA-N n-(2-aminoethyl)-3-(3,5-ditert-butyl-4-hydroxyphenyl)propanamide Chemical compound CC(C)(C)C1=CC(CCC(=O)NCCN)=CC(C(C)(C)C)=C1O BAPROVDXKNPHAM-UHFFFAOYSA-N 0.000 description 1
• RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
• ZKONTOQLRAPWED-UHFFFAOYSA-N n-ethylmorpholin-4-amine Chemical compound CCNN1CCOCC1 ZKONTOQLRAPWED-UHFFFAOYSA-N 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000012169 negative regulation of microtubule polymerization Effects 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 239000008020 pharmaceutical preservative Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 229960005190 phenylalanine Drugs 0.000 description 1
• 235000008729 phenylalanine Nutrition 0.000 description 1
• XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 235000003270 potassium fluoride Nutrition 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• 238000012113 quantitative test Methods 0.000 description 1
• 208000026079 recessive X-linked ichthyosis Diseases 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 238000002390 rotary evaporation Methods 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 231100000735 select agent Toxicity 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 235000013570 smoothie Nutrition 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical class [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000004334 sorbic acid Chemical class 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000020347 spindle assembly Effects 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002948 striated muscle cell Anatomy 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 230000019635 sulfation Effects 0.000 description 1
• 238000005670 sulfation reaction Methods 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 125000002456 taxol group Chemical group 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 208000018726 traumatic encephalopathy Diseases 0.000 description 1
• GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
• 230000006433 tumor necrosis factor production Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 230000001836 utereotrophic effect Effects 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229960004295 valine Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 108010047303 von Willebrand Factor Proteins 0.000 description 1
• 102100036537 von Willebrand factor Human genes 0.000 description 1
• 229960001134 von willebrand factor Drugs 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1